Celia Lin

Celia Lin, MD is a Volunteer Assistant Clinical Professor in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine. She maintains an active clinical and research profile focused on rheumatology, particularly systemic sclerosis (scleroderma) and associated interstitial lung disease. Her work involves multiple clinical trials of immunotherapies, with a special emphasis on tocilizumab (an IL-6 inhibitor) for autoimmune conditions.

Dr. Lin received her MD from the University of Rochester School of Medicine and completed her internal medicine residency at Boston Medical Center, followed by rheumatology fellowships at UCLA and Washington University in St. Louis. Her educational background also includes a BS in General Chemistry with Business and Administration Specialization from UCLA.

Dr. Lin's research interests span rheumatology, immunology, and clinical trial methodology. She has made significant contributions to understanding systemic sclerosis, particularly through her work on biomarkers, clinical endpoints, and therapeutic interventions. Her research has demonstrated how immunotherapies like tocilizumab can impact disease progression in systemic sclerosis and associated interstitial lung disease. She has also contributed to research on autoimmune kidney disease and osteoporosis treatment.

Analysis of her recent publications shows a strong focus on clinical trials methodology, biomarker development, and therapeutic interventions for autoimmune diseases. Her work spans multiple disciplines including rheumatology, pulmonology, nephrology, and endocrinology, with particular emphasis on systemic sclerosis, interstitial lung disease, and immunotherapy approaches.

Dr. Lin has been actively involved in major clinical trials including the focuSSced and faSScinate studies, which have significantly advanced the understanding and treatment of systemic sclerosis. Her work has been cited extensively, with several publications having hundreds of citations, indicating substantial impact in her field.

Her research collaborations extend across multiple institutions, demonstrating her active role in the broader scientific community. She has worked with numerous co-authors on complex multi-center trials, contributing to the advancement of treatment options for patients with challenging autoimmune conditions.